Ausgabe 1/2011
Inhalt (12 Artikel)
Adjuvant chemotherapy in stage IB NSCLC: implication of the new TNM staging system
M. Dediu
Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?
S. I. Rothschild, O. Gautschi
Targeted therapies in advanced non-small cell lung cancer: success or failure?
E. Szutowicz, K. Konopa, J. Jassem
Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO
I. Stenger, C. Tomala, M. Pietsch, U. Olgemoeller, W. Koerber, B. Fischer, M. Sebastian, L. Truemper, T. Overbeck, F. Griesinger
STAT signalling in malignant mesothelioma: Is there a regulatory effect of microRNAs?
L. Arzt, H. Kothmaier, F. Quehenberger, I. Halbwedl, H. H. Popper
Comorbidity – an important domain in elderly cancer patients' assessment
R. Simanek, J. Walczuk, K. Geissler
Associations of serum uric acid and gamma-glutamyltransferase with cancer in the Vorarlberg Health Monitoring and Promotion Programme (VHM&PP) – a short review
M. Edlinger, G. Nagel, W. Hilbe, G. Diem, H. Concin, Alexander M. Strasak, H. Ulmer